Signed in as:
filler@godaddy.com
Invest
Invest with impact.
- By 2035, the global degenerative macular disease market, which would include advanced inherited and age-related varieties with geographic atrophy, is projected to reach $6-8 billion annually.
- Rising rates of age-related eye diseases are expected to drive consumer demand for development of more effective therapies.
- Cell-based therapies are identified as one of the emerging technologies likely to impact the market significantly in 5 to 10 years.
Milestones mean more than words on a slide.
2024 SVT-001 + Suprachoroidal Delivery Wholly-owned IP-patent pending FDA clears first-in-human trial First patient treated 2025 Successful 12-month results Partnership manufacturing, clinical, device FDA clears second trial 2026 - Full trial launch
